Rating Change
Needham analysts reiterated a Buy rating on Immuneering Corporation (NASDAQ:IMRX) on July 20, 2026.
reiterateNASDAQ:IMRX
Needham Reiterates Buy Rating on Immuneering Corporation (IMRX)
Rating Change Needham analysts reiterated a Buy rating on Immuneering Corporation (NASDAQ:IMRX) on July 20, 2026. Market Context Immuneering Corporation operates in the Healthcare…
Market Context
Immuneering Corporation operates in the Healthcare sector. The stock currently trades at $4.64 with a market capitalization of $224.7M.
Analyst coverage from Needham provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Immuneering Corporation.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Immuneering Corporation
Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Jul 20, 2026 | Needham | Buy | N/A |
| Jul 08, 2026 | Cantor Fitzgerald | Overweight | N/A |
| May 19, 2026 | Chardan Capital | Buy | N/A |
| Mar 09, 2026 | Needham | Buy | N/A |
| Nov 13, 2025 | Chardan Capital | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View IMRX Stock Page
Frequently Asked Questions
What does a Buy rating mean for IMRX?
A Buy rating from Needham reflects the analyst's outlook on Immuneering Corporation (NASDAQ:IMRX). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the IMRX forecast page.